Pre-market: Higher opening seen; RIL, United Bank of India in focus

Glenmark Pharma up on plans to out-license molecule for pain management

The molecule, GRC 17536, is expected to have a market potential worth $ 1 billion.

Pre-market: Higher opening seen; RIL, United Bank of India in focus

Glenmark Pharma up on plans to out-license molecule for pain management

The molecule, GRC 17536, is expected to have a market potential worth $ 1 billion.

SGX Nifty

sgxnifty.org@privydomain.com

You may also like...

Discussion on Pre-market: Higher opening seen; RIL, United Bank of India in focus